Search for a Spanish Partner for a Bilateral R&D Project (this document will be shared with potential Spanish companies)

Organization	
Date of Request:	12 Oct 2026
Company name:	Sinai University Arish branch, Egypt
Contact person and title/ designation:	Prof. Emad Mohmaed Tolba M Agamy Professor of prosthodontics and dental implantology
E-mail:	Emad.agamy@su.edu.eg
Phone number:	+201156008877
Mobile number:	
Website:	http://su.edu.eg/

SECTION 1: Your Company Profile *(Please give brief / to the point explanations. For more explanation on any point below, you may add a short paragraph as an annexure, with this document.)*	
Business Sector	Education and research
Company mission or core functions	To deliver high-quality pharmaceutical education and to conduct innovative drug-delivery and nanotechnology research that contributes to the development of the Sinai region and beyond. The Faculty of Pharmacy is committed to preparing qualified pharmacists, advancing pharmaceutical technology, and supporting community pharmaceutical-care needs.
Date of establishment	2006- Sinai University was established by Presidential Decree No. 363 of 2005 (operating under Law No. 101 of 1992, replaced by Law No. 12 of 2009 on Private and National Universities); the Faculty of Pharmacy commenced teaching in 2006.
Ownership (if public and traded, add stock exchange and ticker symbol)	Private, non-profit Egyptian university governed by Law No. 12 of 2009 and its executive regulations (Presidential Decree No. 302 of 2010). Not publicly traded; no stock-exchange listing.
Total number of employees	850
Number of employees in R&D	50

Key products sold or services provided	Education (undergraduate and postgraduate)
Company core technical competences	Teaching, research and scientific publication
Key R&D programs and activities	Dentistry, Pharmacology, Biotechnology, Physical Therapy, Information Technology and Engineering
Examples of accomplishments	- NAQAAE accreditation of the Faculty of Pharmacy (Kantara Branch). - ISO 9001:2015 certification of the University Quality Management System (TÜV NORD Egypt). - Several hundred peer-reviewed publications in high-impact international journals across pharmaceutics, pharmacology, biochemistry, materials science and nanotechnology (see SU Research Publications). - Establishment of the Center for Scientific Research and Sustainable Development (~15 staff) supporting joint research clusters and technology transfer. - Multiple funded research projects, patents filed, and memoranda of understanding with Egyptian, Arab and international universities. - Awarding of more than 70,000 scholarships to undergraduate students (cumulative since 2006)
Company strategic orientation	- To facilitate international research collaboration and technology transfer through development of new biomaterials derived from marine sources. The project aims at translating research findings on adhesive compounds of marine snails into potential technological and commercial applications. The outputs are categorized as: a) one patent, b) three Q1 research papers, and c) one start-up company.

SECTION 2: Partner of Interest *(Please provide a brief summary of the prospective partner company or organization. This summary may address some or all of the points below)*	
Profile of ideal technology partner	A Spanish partner, with an established record in natural - products research, analytical chemistry, pharmacognosy, bioassays, and biochemical/ biological research. A partner is able for contribution of complementary methods and participation in joint project design.
Core technological competencies and expertise	Priority capabilities include: LC-MS/MS; isolation (NMR) for structure elucidation and structural characterization of bioactive compounds; validated *in-vitro* bioassay; molecular/ biochemical pathway analysis; and data analysis where relevant. The specific methods will be agreed on the basis of the final research question.
Other essential qualifications (e.g.: ownership, track records etc.)	Experience with EU GMP and EMA regulatory frameworks for topical and transdermal pharmaceutical products (or medical devices classified under MDR 2017/745); an established Quality Management System (ISO 9001 / ISO 13485); a demonstrable track record of taking laboratory formulations through pilotscale batches to commercial production; capability to host or sponsor ICH-compliant (ICH Q1A) accelerated and real-time stability studies; experience with regulatory dossier preparation for the Egyptian Drug Authority (EDA) and EMA.
If you have a list of companies with whom you are in contact or interested in contacting, please provide contact details	No shortlist yet finalized — partner introductions currently being coordinated through CDTI (Spain) and the EDA (Egypt). Active interest in Spanish companies operating in: (a) topical dermatological formulations and cosmeceuticals, (b) woundcare dressings, hydrogels and bioactive

	matrices, (c) industrial-scale green synthesis of metallic nanoparticles, and (d) GMP contract development and manufacturing (CDMO)
If you are interested in collaboration: please specify details and other important information you want to share with a potential company	The Egyptian team proposes to contribute knowledge of the regional research context, help in defining suitable source materials and research questions, and participate in sample documentation, biochemical/biological evaluation, data interpretation, and subject to facilitate approval of research outputs. The Spanish partner would contribute complementary analytical or advanced experimental skills.
Interested areas of collaboration	1. Characterization of chemical profile of selected natural products as snails 2. Screening of bioactivity related to metabolic/inflammatory or pathological fractures of bone 3. Studies on biochemical mechanisms 4. Separation of different active constituents. 5. Method development and validation 6. Joint publications and applications for future external funding
Specific R&D contribution you are seeking/offering	This study presents an integrated pipeline for developing bio-inspired marine adhesives derived from adhesive marine snails (mollusks) attached to rocks and vessel hulls. The aim is to produce a bio-glue that can be used to enhance bone formation and can reduce the period of healing after inserting dental implants. The methodology spans photographic field-sampling, taxonomic classification, literature mapping, bio-gel extraction, chemical profiling via LC-MS, and molecular identification using gel electrophoresis and DNA

	sequencing. These combined analytical and genetic profiles will guide the biomimetic formulation and synthesis of functional bio-gels from raw precursor materials."

